Methoxamine

DB00723ApprovedInvestigationalWithdrawnSmall molecule

Methoxamine is an alpha adrenergic agonist used to treat hypotension. An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction.

Mechanism: Methoxamine acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic and diastolic).
Curator reviewed
Primary indication: Indicated for the treatment and management of hypotension.Curator reviewed
Formula / weight: C₁₁H₁₇NO₃ · 211.2576 g/mol (avg)
First approval: Canada, 1950
Also known as: Metossamina · Pseudomethoxamine
Code names: NRL-001

Resolves to

Compound

UNIIHUQ1KC1YLICAS390-28-3ChEMBLCHEMBL524ChEBI6839PubChem6082KEGGD08201

Clinical / RWD

RxNorm6853ATCC01CA10PharmGKBPA450431

Structure

InChIKeyWJAJPNHVVFWKKL-UHFFFAOYSA-NSMILESCOC1=CC(C(O)C(C)N)=C(OC)C=C1

Targets

P35348ADRA1AP25100ADRA1DP35368ADRA1B

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

751Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 22 drug categories

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Methoxamine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In